Figure 2.
Responder rates (percentage of subjects with ratings of none or mild) following each of 3 treatments with onabotulinumtoxinA: based on physician’s assessment of glabellar line severity at maximum frown (n = 258; subjects receiving all 3 treatments).
Carruthers A, Carruthers J, Lowe NJ, et al; for the BOTOX® Glabellar Lines I and II Study Groups. One-year, randomised, multicenter, two-period study of the safety and efficacy of repeated treatments with botulinum toxin type A in patients with glabellar lines. J Clin Res. 2004;7:1–20.41 © 2004 Informa Healthcare. Reproduced with permission.
aIndicates that the value is significantly greater than the value at the same time point after one or both previous botulinum toxin treatments (P < 0.028).
Arrow indicates time of botulinum toxin treatment.